BR112013021660A2 - terapias de combinação compreendendo agentes anti-erbb3 - Google Patents
terapias de combinação compreendendo agentes anti-erbb3Info
- Publication number
- BR112013021660A2 BR112013021660A2 BR112013021660A BR112013021660A BR112013021660A2 BR 112013021660 A2 BR112013021660 A2 BR 112013021660A2 BR 112013021660 A BR112013021660 A BR 112013021660A BR 112013021660 A BR112013021660 A BR 112013021660A BR 112013021660 A2 BR112013021660 A2 BR 112013021660A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination therapies
- erbb3 agents
- erbb3
- agents
- therapies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446326P | 2011-02-24 | 2011-02-24 | |
| US201161470848P | 2011-04-01 | 2011-04-01 | |
| PCT/US2012/026602 WO2012116317A2 (en) | 2011-02-24 | 2012-02-24 | Combination therapies comprising anti-erbb3 agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112013021660A2 true BR112013021660A2 (pt) | 2018-06-12 |
Family
ID=46721477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013021660A BR112013021660A2 (pt) | 2011-02-24 | 2012-02-24 | terapias de combinação compreendendo agentes anti-erbb3 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20140056898A1 (https=) |
| EP (1) | EP2678359A4 (https=) |
| JP (1) | JP2014511383A (https=) |
| KR (1) | KR20140053865A (https=) |
| CN (1) | CN103547598A (https=) |
| AU (1) | AU2012222094A1 (https=) |
| BR (1) | BR112013021660A2 (https=) |
| CA (1) | CA2828099A1 (https=) |
| IL (1) | IL228095A0 (https=) |
| MX (1) | MX2013009732A (https=) |
| WO (1) | WO2012116317A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| CA2792327C (en) | 2010-03-11 | 2019-09-24 | Merrimack Pharmaceuticals, Inc. | Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| SG192775A1 (en) * | 2011-03-15 | 2013-09-30 | Merrimack Pharmaceuticals Inc | Overcoming resistance to erbb pathway inhibitors |
| CA2873111A1 (en) * | 2012-05-11 | 2013-11-14 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| IL301147A (en) | 2014-02-28 | 2023-05-01 | Merus Nv | An antibody that binds to ErbB-2 and ErbB-3 |
| EP3786186A1 (en) | 2014-02-28 | 2021-03-03 | Merus N.V. | Antibodies that bind egfr and erbb3 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| CA3002957A1 (en) | 2015-10-23 | 2017-04-27 | Koninklijke Nederlandse Akademie Van Wetenschappen | Binding molecules that inhibit cancer growth |
| MY190153A (en) * | 2016-12-01 | 2022-03-31 | Oxford BioDynamics PLC | Application of epigenetic chromosomal interactions in cancer diagnostics |
| AU2018246873B2 (en) | 2017-03-31 | 2021-05-06 | Merus B.V. | ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene |
| WO2018212656A1 (en) * | 2017-05-17 | 2018-11-22 | Merus N.V. | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer |
| CN118580366A (zh) | 2017-08-09 | 2024-09-03 | 美勒斯公司 | 结合EGFR和cMET的抗体 |
| EP4097140A4 (en) * | 2020-01-29 | 2023-10-18 | Board of Regents, The University of Texas System | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCERS WITH NRG1 GENE FUSIONS |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102282168A (zh) * | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| AU2011341337A1 (en) * | 2010-12-10 | 2013-06-13 | Merrimack Pharmaceuticals, Inc. | Dosage and administration of bispecific scFv conjugates |
-
2012
- 2012-02-24 EP EP12749889.7A patent/EP2678359A4/en not_active Withdrawn
- 2012-02-24 JP JP2013555616A patent/JP2014511383A/ja active Pending
- 2012-02-24 CN CN201280019977.7A patent/CN103547598A/zh active Pending
- 2012-02-24 BR BR112013021660A patent/BR112013021660A2/pt not_active IP Right Cessation
- 2012-02-24 US US14/001,448 patent/US20140056898A1/en not_active Abandoned
- 2012-02-24 WO PCT/US2012/026602 patent/WO2012116317A2/en not_active Ceased
- 2012-02-24 KR KR1020137025188A patent/KR20140053865A/ko not_active Withdrawn
- 2012-02-24 MX MX2013009732A patent/MX2013009732A/es not_active Application Discontinuation
- 2012-02-24 CA CA2828099A patent/CA2828099A1/en not_active Abandoned
- 2012-02-24 AU AU2012222094A patent/AU2012222094A1/en not_active Abandoned
-
2013
- 2013-08-22 IL IL228095A patent/IL228095A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140053865A (ko) | 2014-05-08 |
| CN103547598A (zh) | 2014-01-29 |
| MX2013009732A (es) | 2013-12-06 |
| WO2012116317A2 (en) | 2012-08-30 |
| EP2678359A2 (en) | 2014-01-01 |
| CA2828099A1 (en) | 2012-08-30 |
| WO2012116317A3 (en) | 2013-11-14 |
| AU2012222094A1 (en) | 2013-10-10 |
| JP2014511383A (ja) | 2014-05-15 |
| IL228095A0 (en) | 2013-09-30 |
| US20140056898A1 (en) | 2014-02-27 |
| EP2678359A4 (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301241I2 (nl) | Belantamab mafodotin | |
| BR112013021660A2 (pt) | terapias de combinação compreendendo agentes anti-erbb3 | |
| EP2663304A4 (en) | COMBINATION THERAPY | |
| CO6862160A2 (es) | Indazoles | |
| PT2720563T (pt) | Resumo | |
| DK2769050T3 (da) | Propsensor | |
| PT2543357T (pt) | Resumo | |
| DE102011100082A8 (de) | Traygreifvorrichtung | |
| EP2761267A4 (en) | CALIBRATION OF A BREATHING ANALYZER | |
| BR112013033974A2 (pt) | terapia de combinação | |
| DE112012005067A5 (de) | Antriebsstrang | |
| DK2760886T3 (da) | Immunocytokin-kombinationsterapi | |
| FI20115876A0 (fi) | Yhdistelmähoito | |
| DE112012002790A5 (de) | Antriebsstrang | |
| BR112014000879A2 (pt) | deflegmador | |
| CO6960543A2 (es) | 2-tiopirimidinonas | |
| EP2791653A4 (en) | PROCESS FOR OPTIMIZED SCATTEROMETRY | |
| EP2914254A4 (en) | COMBINATION THERAPIES | |
| PT2661870T (pt) | Resumo | |
| EP2663189A4 (en) | Combination | |
| IL229081A0 (en) | Isoxazolines as therapeutic agents | |
| SMT201600441B (it) | Nuovi agenti antimalarici | |
| EP2720718A4 (en) | ANTI-CD3 THERAPIES | |
| PT2836483T (pt) | Agentes antimalária | |
| DE112011104936A5 (de) | Stanzstauchniet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2476 DE 19-06-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |